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IMMUNOBIOLOGY
The lymphoproliferative defect in CTLA-4–deficient mice is ameliorated
by an inhibitory NK cell receptor
Cynthia A. Chambers, Joonsoo Kang, Yongjian Wu, Werner Held, David H. Raulet, and James P. Allison
T-cell responses are regulated by activat-
ing and inhibiting signals. CD28 and its
homologue, cytotoxic T-lymphocyte anti-
gen 4 (CTLA-4), are the primary regula-
tory molecules that enhance or inhibit
T-cell activation, respectively. Recently it
has been shown that inhibitory natural
killer (NK) cell receptors (NKRs) are ex-
pressed on subsets of T cells. It has been
proposed that these receptors may also
play an important role in regulating T-cell
responses. However, the extent to which
the NKRs modulate peripheral T-cell ho-
meostasis and activation in vivo remains
unclear. In this report we show that NK
cell inhibitory receptor Ly49A engage-
ment on T cells dramatically limits T-cell
activation and the resultant lymphoprolif-
erative disorder that occurs in CTLA-4–
deficient mice. Prevention of activation
and expansion of the potentially autoreac-
tive CTLA-4/ T cells by the Ly49A-
mediated inhibitory signal demonstrates
that NKR expression can play an impor-
tant regulatory role in T-cell homeostasis
in vivo. These results demonstrate the
importance of inhibitory signals in T-cell
homeostasis and suggest the common
biochemical basis of inhibitory signaling
pathways in T lymphocytes. (Blood. 2002;
99:4509-4516)
© 2002 by The American Society of Hematology
Introduction
Cytotoxic T-lymphocyte antigen 4 (CTLA-4), a homologue of the
T-cell costimulatory molecule CD28, is proposed to regulate the
initiation and termination of T-cell responses. Accumulating in
vitro and in vivo evidence suggests that CTLA-4 engagement
inhibits T-cell activation (reviewed in Chambers et al1). CTLA-4
engagement inhibits the up-regulation of early activation T-cell
surface antigens, prevents cell cycle transit, and inhibits secretion
of interleukin 2 (IL-2), whereas CTLA-4 blockade enhances T-cell
responses.2 The strongest evidence for the inhibitory role of
CTLA-4 has been demonstrated in CTLA-4–deficient mice. CTLA-
4/ mice develop a fatal lymphoproliferative disorder character-
ized by a massive expansion of lymphocytes dependent initially on
polyclonal, CD28-dependent activation of CD4 T cells, subse-
quent lymphocytic infiltration into nonlymphoid tissues, and death
by 3 to 4 weeks of age.3-6 Polyclonal CD4 CTLA-4–deficient
T-cell activation is observed in the absence of immunization and
exogenous antigen, as demonstrated in mice expressing a single
self-peptide/major histocompatibility complex (MHC) class II
complex (C.A.C., manuscript in preparation). We propose that
CTLA-4 provides dominant inhibitory signals to prevent autoreac-
tive peripheral T-cell activation and maintain T-cell homeostasis.5
Accordingly, this model predicts that the lymphoproliferation
observed in CTLA-4/ mice may be prevented by an alternate
inhibitory signal.
Natural killer (NK) cells are a subset of effector lymphocytes
that can directly lyse transformed target cells without prior
priming. The activation of NK cells is in part controlled by
inhibitory molecules that recognize MHC class I molecules. The
murine inhibitory NK receptors (NKRs) fall into 2 groups: a family
of lectinlike Ly49 molecules and CD94/NKG2 heterodimers. Each
of the Ly49 molecules demonstrates a unique and specific MHC
class I recognition pattern. For example, the Ly49A molecule binds
relatively strongly to H-2Dd and weakly to Dk,s,b haplotypes on
target cells.7,8 Inhibitory Ly49 molecules were initially character-
ized as NK-specific receptors that provide dominant inhibitory
signals and prevent NK cell lysis of targets in the presence of the
specific self-MHC molecules. NK lysis would then occur on
decreased or loss of expression of MHC class I molecules on the
surface of target cells, an alteration often observed during transfor-
mation and some viral infections.
Recently, it has been shown that the inhibitory NKRs are more
widely expressed than initially suspected. Varying proportions of
NKT,  T cells and human and murine  CD8 T cells with
memory phenotype express the inhibitory NKR.9-13 Based on this
expression pattern, it has been proposed that these receptors might
also regulate T-lymphocyte activation or T-cell responses. Results
with T-cell clones demonstrate that human inhibitory and activating
NKR, namely KIRs and KARs, respectively, can influence T-cell
cytotoxicity in vitro.14-18 In vitro mixed lymphocyte reactions by
murine CD4 T cells are also inhibited by the engagement of
Ly49A.19 Recently, it has been shown that lymphocytic choriomen-
ingitis virus (LCMV)–specific cytotoxic T-lymphocyte (CTL)
responses and antitumor responses are decreased following immu-
nization when CD8 T cells express Ly49A transgene,20,21 showing
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that NKRs on T cells can modulate antigen-specific responses.
However, the physiologic importance of NKR-mediated inhibition
in regulating mature peripheral T-cell homeostasis and tolerance in
vivo is unknown. Moreover, the biochemical pathways used by
these inhibitory signals and how they interact/intersect with T-cell
receptor (TCR)–mediated signaling pathways are unclear.
In this study we examined the potential of inhibitory NKRs to
regulate systemic autoreactive T-cell activation and tested the
ability of an alternative inhibitory signal to compensate for the loss
of CTLA-4–mediated signals in T-cell homeostasis. We show that
introduction of the Ly49A transgene (Tg)19 into CTLA-4–deficient
mice22 expressing H-2Dd regulates the lymphoproliferative disease
associated with the loss of CTLA-4 function: Ly49A expression on T
cells inhibits the activation and the accumulation of the CTLA-4/ T
cells only in the presence of Ly49A ligand H-2Dd. The prevention of
rampant proliferation of CTLA-4/ T cells by the Ly49A-mediated
inhibitory signals is accompanied by a selective decrease in the level of
tyrosine phosphorylation of proteins involved in the signaling pathways
for T-cell activation. Collectively, these results demonstrate that engage-
ment of Ly49A receptors on T cells can compensate for the loss of
CTLA-4 function and prevent activation of the autoreactive T cells in
vivo. These results demonstrate the role of inhibitory receptors, includ-
ing inhibitory NKRs in maintaining peripheral T-cell homeostasis and
tolerance.
Materials and methods
Mice
Mice heterozygous for the CTLA-4 null mutation22 were backcrossed 3
times to C57BL/6 before being crossed to mice expressing the Ly49A
transgene (MHC class I promoter, IgM enhancer) and H-2Dd (B10.D2).19
The Ly49ATg mice used in this study are healthy and display no
pathogenesis,19 in contrast to other strains of mice that develop autoimmu-
nity due to altered thymocyte selection.24 Mice heterozygous for the Ly49A
transgene, H-2Dd, and the CTLA-4 mutation were intercrossed to obtain
Ly49A transgenic, H-2Dd, CTLA-4/, CTLA-4/, and CTLA-4/
animals. Similar results have been obtained with animals that are more
extensively backcrossed to the B6 background ( 6 times). Animals were
typed for the genotype of the ctla-4 gene by polymerase chain reaction and
for the presence of the transgene and MHC class I by flow cytometric
analysis of peripheral blood lymphocytes. Animals were maintained in
microisolators in accordance with the Animal Care and Use Regulations of
the University of California, Berkeley, and University of Massachusetts
Medical School.
Media and reagents
RPMI (Biowhittaker, Walkersville, MD) was supplemented with 10% calf
serum (Hyclone, Logan, VT), 2 mM 2-mercaptnoethanol (Sigma, St Louis,
MO), 2 mM L-glutamine, and 100U/mL antibiotics (Gibco, Gaithersburg,
MD). Recombinant human IL-2 was obtained from Cetus. Aminoethyl
carbazole (AEC) substrate was obtained from Sigma. Streptavidin-
horseradish peroxidase (HRP) was obtained from Jackson Immunoresearch
Lab (West Grove, PA). The following monoclonal antibodies (mAbs) were
used: anti-CD4-phycoerythrin (PE)/tricolor (TC), anti-CD44-PE, H57-
biotin (anti-TCR), anti-CD69-fluoroescein isothiocyanate (FITC)/biotin,
anti-CD25-FITC, anti-thy1.2-PE/FITC, anti-CD62L-PE, anti-CD45RB-
FITC, anti-Sca-1-FITC (all from Pharmingen, San Diego, CA); anti-B220-
FITC, anti-CD8-TC, streptavidin-TC, -PE (Caltag, Burlingame, CA);
anti-CD4-613 and CD8-613 (Gibco). Anti-Ly49A antibody YE5 was
prepared as described in Held et al.19 Anti–bromodeoxyuridine (anti-BrdU)
antibody was purchased from Becton Dickinson. Annexin V staining kit
was purchased from Pharmingen. In some annexin V staining experiments,
propidium iodide was used to exclude dead cells from analysis. Flow
cytometric analysis was performed as described.22
Histologic analysis
Tissue samples from the pancreas, liver, lung, heart, skin, and kidney were
routinely removed. The samples were fixed in 10% buffered formalin and
embedded in paraffin. Sections were fixed on slides and stained with
hematoxylin and eosin by conventional techniques.
Cell preparation and flow cytometric analysis
For all of the mice analyzed the caudal, mesenteric, brachial, submaxillary,
inguinal, and popliteal lymph nodes were collected and pooled. Single-cell
suspensions were prepared from the pooled nodes and the spleen and,
following red blood cell lysis, the cells were counted and used for analysis.
Flow cytometric analysis was performed as described. Briefly, cells
(0.5-1  106 cells/sample) were preincubated with 24G2 to block FcR and
were then incubated with the indicated antibodies. For annexin V staining
the samples were prepared as above, but were also incubated with the
annexin V staining kit as per the instructions (Pharmingen). The samples
were analyzed on a 4-color flow cytometer (XL; Coulter, Hialeah, FL) and
50 000 events were collected per sample. The listmode files were analyzed
using WINMIDI software. The statistical significance of the absolute cell
numbers in the groups of animals analyzed were compared using the
Student t test.
BrdU incorporation analysis
Animals were injected every 9 to 12 hours (100 	g/mouse) for 2 days and
analyzed 12 hours or 3 days after the last injection, as described.5,22 Briefly,
samples from the lymph node and spleen were stained for cell surface
markers and fixed with 70% ethanol, followed by paraformaldehyde
treatment. The fixed cells were digested with DNase I and incubated with
anti-BrdU–FITC antibody, as described.22 The cells were washed exten-
sively and immediately analyzed by fluorescence-activated cell sorting, as
described above. Routinely, 50 000 or 100 000 events were collected.
Western blotting and immunoprecipitation
Lymph node T cells were purified ex vivo by negative enrichment using
anti-B220 beads (Dynal, Oslo, Norway) to ensure that the purification
procedure was performed rapidly and at 4°C. The purity of the cell
preparation was confirmed by flow cytometry. Lysates from purified lymph
node T cells were prepared as described,23 at a concentration of 1  107
cells/100 	L NP-40 lysate buffer. Protein concentrations were determined
using the Protein Assay Kit (Biorad, Hercules, CA). To further ensure that
equal amounts of protein were loaded on the gel or used for the
immunoprecipitation, varying volumes of the sample lysates were run on a
gel and analyzed by standard Western blotting. The proteins were resolved
on 8%, 10%, or 12% polyacrylamide gels. Western blot analysis was
performed as described.23 Tyrosine phosphorylated proteins were detected
using 4G10-biotin and developed with SA-HRPO (Upstate Biotechnology,
Lake Placid, NY). The blots were stripped and reprobed with antibodies to
the indicated proteins, namely, ERK2, cbl, ZAP-70, SHP-1, SHP-2, PLC1,
vav (all from Santa Cruz Biotechnology, Santa Cruz, CA). Equal amounts
of protein of the indicated samples were immunoprecipitated as described.24
Anti-CD3
 antibody 387 was a gift of L. Samelson.
Results
Ly49A ligation inhibits T-cell activation and expansion in
CTLA-4–deficient T cells
The Ly49ATg mice used in this experiment are healthy, contain
normal numbers of T cells, and have no overt alterations in
thymocyte development.19 Ly49A is expressed at high levels on all
T cells in these animals. To test if the alternate inhibitory signal
mediated by Ly49A could compensate for the loss of the putative
inhibitory signal via CTLA-4, the Ly49A transgene was introduced
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into the CTLA-4–deficient mice. Expression of the Ly49A trans-
gene on T cells in H-2Dd CTLA-4–deficient mice results in a
10-fold reduction in the absolute number of lymph node CD4 T
cells compared to Ly49ATg H-2b (Db) CTLA-4/ (P  .001) or
nontransgenic CTLA-4/ mice (P  .001) and leads to a restora-
tion of a T-cell pool comparable in size (no statistically significant
difference) to that of normal mice (Figure 1). There is a 2- to 3-fold
or a 5- to 6-fold decrease in the proportion of CD4 T cells in
Ly49ATg H-2d CTLA-4/ mice compared to wild-type or
Ly49ATg H-2b CTLA-4/ mice, respectively. Similar results
were observed in the spleen although it appeared that the propor-
tion of total T cells in the spleen was more strikingly reduced in
Ly49Tg H-2d CTLA-4/ mice compared to the wild-type
controls (data not shown). CD4 T cells in Ly49Tg CTLA-4/
mice expressing H-2Dd exhibit a diminished activation phenotype
compared to the CD4 T cells in Ly49ATg H-2b CTLA-4/
mice, and display a phenotype similar although not identical to the
T cells in CTLA-4 wild-type mice (Figure 2). Most strikingly, the
H-2d CTLA-4/ T cells expressing the Ly49A transgene showed a
significantly reduced proportion of CD69, CD44high, and
CD45RBlow activated T cells compared to the H-2b CTLA-4–
deficient T cells that do not express the appropriate Ly49A ligand
(Figure 2).
Down-modulation of the Ly49ATg receptor cell surface expres-
sion occurs in the presence of the H-2Dd ligand,19 as has been
shown to occur for the endogenous Ly49 molecules.24 The CD44high
T cells in the Ly49ATg H-2Dd CTLA-4/ mice are predomi-
nantly Ly49Tglow, suggesting that after Ly49A receptor engage-
ment and consequent decrease in cell surface expression of the
receptor, some CTLA-4/ T cells may become activated (data not
shown). Hence, sustained and complete prevention of the lympho-
proliferative disorder due to the absence of CTLA-4 appears to
require persistent expression of the Ly49A inhibitory receptors.
Figure 1. Expression of Ly49A transgene in the presence of MHC class I H-2Dd
prevents lymphocyte expansion in CTLA-4–deficient mice. Single-cell suspen-
sions of lymph node cells were prepared, counted, and analyzed for the expression of
cell surface markers using antibodies specific for CD4, CD8, and TCR. Absolute
number of CD4 in Ly49ATg H-2b/H-2d, CTLA-4 wild-type and deficient animals.
Each dot represents a single animal. Ly49ATg H-2Db: CTLA-4/,/, n  9;
CTLA-4/, n  9; Ly49ATg H-2Dd CTLA-4/,/, n  31; CTLA-4/, n  18.
These animals were analyzed at 3 to 5 weeks of age, because the CTLA-4/ mice
that develop the lymphoproliferative disease die by 4 weeks of age. The difference in
the absolute CD4 T-cell number in the CTLA-4/ mice expressing Ly49A transgene
in the presence versus absence of the ligand H-2Dd was statistically significant
(P  .001), whereas there was no statistically significant difference in the number of
CD4 T cells between the Ly49ATg H-2Dd CTLA-4/ and the littermate
control mice.
Figure 2. Ly49A-mediated inhibitory signals upon interaction with H-2Dd prevent the activation of CD4 T cells. Representative flow cytometric analysis of CTLA-4/
T cells from animals expressing the Ly49ATg in the presence and absence of the appropriate MHC class I compared to Ly49ATg CTLA-4/ mice and littermate controls
(3 weeks of age). Lymph node cells were incubated with the antibodies indicated and analyzed by flow cytometry as described.22 (A) Total lymph node T cells were stained for
CD4 and CD8. (B) The expression of the indicated activation/memory cell surface markers on the CD4 lymph node T cells from Ly49ATgDb CTLA-4/, Ly49ATg H-2Dd
CTLA-4/ and littermate control mice. The Ly49ATgDb CTLA-4/ T cells have an activated phenotype similar to that observed in Ly49ATg CTLA-4/ mice (data not
shown; see also Chambers et al5). These results are representative of more than 10 independent experiments.
Ly49A PREVENTS CTLA-4/ T-CELL ACTIVATION 4511BLOOD, 15 JUNE 2002  VOLUME 99, NUMBER 12
 For personal use only. at UNIV OF MASSACHUSETTS on April 3, 2008. www.bloodjournal.orgFrom 
This result is consistent with the model that the CTLA-4/ T cells
are receiving continuous activating signals even in the absence of
exogenous antigen stimulation in vivo.
Lymphocytic infiltration into nonlymphoid tissues in CTLA-
4/ mice is inhibited by the ligation of Ly49A. CTLA-4/ mice
display extensive infiltration of lymphoid cells into nonlymphoid
tissues such as the liver, heart, lung, and pancreas that results in a
severe pancreatitis and fatal myocarditis in CTLA-4/ animals.3-5
Similarly, extensive lymphocytic infiltration into the liver, pancreas
(representative data shown in Figure 3), heart, and skin (data not
shown) was observed in the Ly49ATg H-2Db CTLA-4/ mice
compared to the littermate CTLA-4/, CTLA-4/ controls
(Figure 3). In contrast, histologic analysis of tissues from Ly49ATg
H-2Dd CTLA-4/ mice showed a greatly diminished infiltration of
lymphocytes into nonlymphoid tissues compared to those of
Ly49ATg/H-2Db CTLA-4–deficient mice (Figure 3: liver, pan-
creas; lung, heart, data not shown). These results demonstrate that
the expression of an NK cell inhibitory receptor on T cells prevents
Figure 3. Ly49A transgene interaction with H-2Dd prevents the infiltration of lymphocytes into nonlymphoid tissues in CTLA-4–deficient mice. Dramatic infiltration of
the nonlymphoid tissues was observed in the CTLA-4/ mice expressing the Ly49ATg in the absence of MHC class I-Dd, whereas there was no apparent T-cell infiltration in the
Ly49ATg H-2Dd CTLA-4/ mice. Tissues were fixed in 10% buffered formalin and embedded in paraffin blocks. Sections were cut and stained with hematoxylin and eosin by
conventional techniques. The representative data shown (of  10 independent experiments) are tissue sections from liver (A) and pancreas (B) of animals 3.5 weeks of age.
No overt lymphocytic infiltration into nonlymphoid tissue was observed in the Ly49ATg H-2Dd CTLA-4/ mice at 5 to 6 weeks of age (data not shown). Magnification, 250.
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aberrant T-cell infiltration of tissues in the CTLA-4/ mice, as
well as inhibiting T-cell activation. Similarly there was no overt
lymphoproliferation in the Ly49ATg H-2Dd CTLA-4/ at 5 to 6
weeks of age (data not shown).
Ly49A ligation inhibits T-cell activation and proliferation
by inhibiting the number of cells in the cell cycle
and by increased cell death
The cellular and biochemical basis for the rescue of the CTLA-4
deficiency by Ly49ATg-mediated signals was examined. To
determine if the compensatory signal prevented T-cell division,
we measured the incorporation of thymidine analog BrdU
following continuous labeling, as well as the rate of decay of
incorporated BrdU in the T cells. There was a 2.7- to 4.5-fold
increase in the percentage of CD4 T cells positive for BrdU
incorporation in the CTLA-4/ mice compared to CTLA-4
wild-type mice (Figure 4), as previously described.5 The
expression of the Ly49A transgene did not significantly alter the
level of BrdU incorporation in T cells in the normal mice (Db or
Dd background, data not shown). There was a 2- to 3-fold
decrease in the percentage of BrdU CD4 T cells in the lymph
node (Figure 4A) and spleen (data not shown) in Ly49ATg
H-2Dd CTLA-4/ mice compared to the Ly49ATg
H-2DbCTLA-4/ or Ly49ATg CTLA-4/ mice. Following a
3-day chase, the proportion of the CD4 T cells staining for
BrdU incorporation decreased dramatically in the CTLA-4/
mice to one sixth the level detected after the 2-day pulse. For
both control and rescued CTLA-4/ mice the remaining BrdU
incorporation in CD4 T cells was decreased less than 2-fold
compared to the levels at 2-day pulse. The difference for CD8
T cells was less striking, although the levels of BrdU labeling
decreased 3-fold in CTLA-4/ mice following the chase,
whereas there was a minimal decrease in the proportion of
BrdU-staining cells for control or rescued CTLA-4/ mice.
These results indicate that T cells from the rescued CTLA-4/
(Ly49ATgH-2Dd) mice, particularly CD4 T cells, have a
decelerated turnover rate compared to the CTLA-4–deficient T
cells. Ly49A-mediated signaling in T cells maintains a near-
normal rate of turnover in the absence of CTLA-4–mediated
signals. These results indicate that prevention of T-cell activa-
tion by Ly49A-mediated inhibitory signals is one mechanism
important for preventing the lymphoproliferative disorder in
CTLA-4/ mice.
Another possible mechanism that could result in decreased
cellularity in the H-2Dd CTLA-4/ mice expressing the Ly49A
transgene could be an increase in the proportion of cells undergoing
cell death. To examine this possibility the proportion of the cells
staining with annexin V, a protein that binds to membrane
phospholipid phosphatidylserine on the surface of apoptotic cells
was examined. As shown in Figure 4B, there was an increase in the
proportion of annexin V CD8 T cells in the spleen of Ly49ATg
H-2Dd CTLA-4/ mice compared to the nontransgenic CTLA-
4/ mice and wild-type controls. The enhanced frequency of
annexin V cells was particularly noticeable for the splenic CD8
T cells (Ly49ATg H-2Dd CTLA-4/: 57.8%  6.3% [average 
SEM], n  4; Ly49ATg H-2Db CTLA-4/: 34.9%  8.8%,
n  4; P  .05, Student t test). A difference in the percentage of
annexin V CD4 T cells in the Ly49ATg H-2Dd T cells was
consistently observed, although it was not statistically significant
(Ly49ATg H-2Dd CTLA-4/: 25.2%  6.3% versus Ly49ATg
H-2Db CTLA-4/: 16.8%  8.8%). Collectively, these results
suggest that the Ly49A transgene rescued the CTLA-4–deficient
phenotype by a combination of prevention of T-cell activation
leading to a decrease in T-cell turnover, and an increase in T-cell
death. Both mechanisms result in an overall reduction in the
absolute number and proportion of peripheral T cells.
Ly49A ligation reverses the tyrosine hyperphosphorylation of
some of the proteins in the early and late signaling pathways
in CTLA-4/ T cells
The absence of CTLA-4 results in tyrosine hyperphosphoryla-
tion of a number of proteins involved in the TCR signaling
pathway.25 To determine if this pattern is modulated by the
Ly49A-mediated inhibitory biochemical signals, the quantity
Figure 4. Ly49A-mediated inhibition decreases the
total lymphoid cellularity by decreasing the T-cell
turnover and survival. (A) Mice were pulsed for 2 days
with BrdU and the remaining levels of BrdU incorporation
after the indicated chase times were detected by flow
cytometry as described in “Materials and methods.”
(B) Annexin V binding was assessed on the lymphocytes
ex vivo, as an indicator of apoptosis. The cells were
incubated with the indicated antibodies and annexin V
and analyzed by flow cytometry as described in “Materi-
als and methods.” These data are representative of 3
independent experiments. In all experiments mice were
approximately 3 weeks of age at the time of analysis.
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and quality of total tyrosine phosphorylation in the purified
lymph node T cells ex vivo from the rescued Ly49ATg H-2Dd
CTLA-4/ animals compared to CTLA-4/ and wild-type
control animals was examined. Hyperphosphorylation of a
number of proteins was detected in lysates of purified lymph
node T cells ex vivo from Ly49ATg H-2Db CTLA-4/ mice
(Figure 5A), as has been reported for CTLA-4/ mice.25 In the
presence of Ly49ATg ligation by MHC class I Dd, the pattern
of total tyrosine phosphorylation in the CTLA-4/ mice was
altered and was very similar to the littermate control (Figure
5A). Most strikingly, there was a decreased level of phosphory-
lation of bands corresponding to p110, p42, p36, and a number
of proteins between p55 and 80 kd (Figure 5A) and 20 to 25 kd
(data not shown). Tyrosine phosphorylation patterns of several
other proteins implicated in T and NK cell signaling, including
Vav and PLC1, did not appear to be differentially phosphory-
lated between the rescued Ly49ATg H-2Dd CTLA-4/ or the
Ly49ATg/H-2Db CTLA-4/ mice (data not shown).
One of the proteins that had decreased tyrosine phosphorylation
in the Ly49ATg H-2Dd CTLA-4/ T cells was mitogen-activated
protein kinase ERK2 (Figure 5B), a downstream component of the
ras signaling pathway (for a review, see Cantrell26). ERK2 phosphor-
ylation is reported to be dependent on TCR signaling and indepen-
dent of CD28-mediated signals. The decrease in ERK2 phosphory-
lation is consistent with the observed inhibition of the early
activation marker CD69 expression strikingly apparent in the
CD4 T cells in the rescued Ly49ATg H-2Dd CTLA-4/ mice
(Figure 2) because CD69 expression is induced in a CD28-
independent, Ras-dependent manner.27
Phosphorylation of the CD3
 chain is one of the most proximal
events in TCR-mediated T-cell activation (for a review, see van
Leeuwen et al28). In freshly isolated thymocytes and peripheral T
cells, the CD3
 ITAM motifs are partially phosphorylated (p21).29,30
On optimal T stimulation, CD3
 ITAM tyrosine phosphorylation is
saturated and the completely phosphorylated CD3
 (molecular
weight of 23Kd [p23]) becomes the predominant form.29,30 Interest-
ingly, there is an increase in the p21 species in the CTLA-4/ T
cells ex vivo. Further, the p21 form remained the dominant
phosphorylated form of CD3
 (Figure 5C), with the fully phosphor-
ylated p23 form of CD3
 below detection in the CTLA-4/ T cells
despite the fact that these T cells are activated and are dividing in
vivo. In Ly49ATg H-2Dd CTLA-4/ lymph node T cells the
overall pattern of CD3
 phosphorylation is similar to littermate
controls, but importantly, the level of tyrosine phosphorylation of
the p21 form of CD3
 significantly decreased compared to the
CTLA-4/ T cells (Figure 5C). These results indicate that Ly49A
ligation reduces the level of tyrosine phosphorylation of CD3
 in T
cells in vivo and suggests that modulation of lymphoproliferation
of CTLA-4/ T cells by Ly49A molecule is mediated in part by
inhibiting proximal TCR signaling as well as the more distal Ras
signaling pathway.
Discussion
Functional complementation of the ctla-4 mutation by an alternate
dominant inhibitory receptor provides compelling evidence for the
model that inhibitory signals play a crucial role in the maintenance
of homeostasis of T cells. Previously we proposed a model for the
role of CTLA-4 in regulating T-cell activation and the integration
of the TCR, CD28, and CTLA-4 signals.31 It has been shown that
continuous, low-level TCR signaling provides signals involved in
peripheral T-cell survival/homeostasis.32-35 An extreme interpreta-
tion of the proposed model is that CTLA-4–mediated inhibitory
signals function to prevent TCR interactions with self-MHC of
sufficient affinity to generate stimulatory signals, in the presence of
low levels of CD28/B7 interaction, from leading to full T-cell
activation and thereby maintaining the T cells in a resting state.5
The results presented here demonstrate that an alternative dominant
inhibitory signal can prevent CTLA-4/ T-cell activation, provid-
ing support for this model of CTLA-4 function.
The function of Ly49A in this model system is absolutely
dependent on the presence of its cognate ligand H-2Dd. Overall,
both CD4 and CD8 T cells showed decreased cell turnover in
Ly49ATgCTLA-4/ mice compared to CTLA-4/ mice. How-
ever, CD8 T cells appeared to be more susceptible to apoptosis in
these mice compared to CD4 T cells (Figure 4). In a study
examining the inhibitory NKR (KIR) function in CD8 T cells, it
has recently been reported that the KIR expression promotes
accumulation of memory CD8 T cells by moderating activation-
induced cell death (AICD).36 This difference in the outcome for
CD8 T-cell survival on inhibitory NKR expression—enhanced
apoptosis versus resistance to AICD—may be explained by distinct
genetic components used in these 2 model systems. More interest-
ingly, however, the difference may arise as a result of different
activational status of CD8 T cells in each system. In the KIR
transgenic model system detection of increased numbers of memory
CD8 T cells required strong antigenic stimulation, whereas the
CTLA-4/ T cells in our model are stimulated to proliferate in the
absence of foreign antigenic challenge. Hence, the activating
stimuli, and the activational history of the T cells, may dictate the
ultimate outcome of inhibitory NKR signaling. It has been
Figure 5. Ly49A-mediated inhibitory signals diverge and converge with the
CTLA-4 signaling pathway. (A) Total tyrosine phosphorylation in lysates of purified
lymph node T cells ex vivo. Lysates were equalized for total protein content and the
proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis (SDS-PAGE; 8%; lane 1: Ly49ATg Dd CTLA-4/,/; lane 2: Ly49ATg Dd
CTLA-4/; lane 3: Ly49ATg Db CTLA-4/). The phosphoproteins were detected by
Western blotting using antiphosphotyrosine antibody 4G10. These data are represen-
tative of 7 independent experiments. Asterisks indicate bands uniquely phosphory-
lated in the CTLA-4/ T cells from mice that develop lymphoproliferation but not in
the “rescued” (Ly49ATg/ Dd) CTLA-4/ or in the littermate control animals.
(B) Phosphorylated ERK2 was detected by Western blot total protein with anti-EK2
tyrosine phosphorylation–specific antibody. The blots in panels A and B were stripped
and reprobed with anti-ERK2 antibody (lanes are as indicated in panel A ). This is
representative of 3 independent experiments. (C) CD3
 phosphorylation. Lysates of
equivalent total protein were immunoprecipitated by anti-CD3
 antibody 387. Immu-
noprecipitates (lanes are as indicated in panel A) were separated by SDS-PAGE
(12%) and phosphoproteins were detected by Western blotting using antiphosphoty-
rosine antibody 4G10. The blots were stripped and reprobed with anti-CD3
 antibody.
This is representative of 3 independent experiments.
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proposed that expression of inhibitory NKR on activated virus-
specific murine CD8 T cells preferentially dampens the activation
and expansion of low affinity CD8 T cells, thereby resulting in
the expansion of high-affinity CD8 T cells that are less
sensitive to inhibitory NKR signaling.20,37 The low-affinity
effector CD8 T cells expressing inhibitory NKR may then be
subject to apoptosis. Increased apoptosis in Ly49ACTLA-4/
CD8 T cells may be mimicking the fate of low-affinity CD8
effector T cells and is consistent with the idea that inhibitory
NKR signaling can act as an apoptosis promoter of CD8 T cells
under some stimulation conditions.37 Further genetic and bio-
chemical characterization will be required to determine how the
physiology of the CD8 T cells influences the fate of the T cell
upon NKR ligation in vivo.
Although the Ly49A transgene interaction with H-2Dd clearly
prevents the lymphoproliferative disorder and lymphocytic infiltra-
tion into nonlymphoid tissues in the CTLA-4/ mice, these mice
do eventually become ill. The Ly49ATg/Dd CTLA-4/ animals
die at approximately 5 to 6 weeks of age of a wasting disease. This
disease is not due to expression of the Ly49A transgene, because
the transgenic mouse line used in this study has been shown to
remain healthy.19 One explanation for the wasting disease observed
in the “rescued” CTLA-4/ mice is the existence of an additional
pathologic component of the CTLA-4 deficiency that is masked by
the lymphoproliferation in CTLA-4/ mice, and for which the
Ly49A-mediated inhibitory signals cannot compensate. Interest-
ingly, reconstitution of normal histocompatible mice with CTLA-
4/ bone marrow (100%) does not recapitulate the lymphoprolif-
eration observed in mice deficient for CTLA-4.38 Instead, these
mice develop a fatal wasting disease that phenotypically resembles
graft-versus-host disease.38 Although it remains controversial,40 it
has been postulated that suppression mediated by transforming
growth factor  (TGF-) is deficient in the CTLA-4/ bone
marrow chimeric animals and in several other models of autoimmu-
nity, due to the absence of CTLA-4 immunoregulatory T cells.38-41
Using the model system described here, it will be possible to
determine if there are distinct mechanisms regulating the lympho-
proliferative and the wasting disorders. Alternatively, the inflamma-
tion and eventual illness in the absence of lymphoproliferation may
be as a result of altered cytokine production due to the Ly49A-
mediated inhibition. These possibilities are not mutually exclusive
and delineation of them will provide insights into the pathologic
components of the CTLA-4 deficiency as well as in understanding
the function of NKR in regulating T-cell homeostasis.
Ultimately, understanding how T cells are normally regulated
by inhibitory signals requires biochemical identification of physio-
logically relevant intracellular signal transducers and substrates.
There is clear evidence for the role of tyrosine phosphatase activity
in Ly49A-mediated inhibitory signals. Although SHP-2 and SHIP
can bind to the Ly49A ITIM motifs, SHP-1 appears to be the
primary phosphatase required for signal transduction (for a review,
see Lanier43). Inhibitory NKR engagement prevents early protein
tyrosine kinase (PTK)–dependent activation signals in NK cell
lines. The picture for CTLA-4 signaling is less clear. There is
considerable controversy concerning the mechanism(s) of CTLA-4
inhibition of T-cell activation. Tyrosine hyperphosphorylation of a
number of proteins involved in TCR signaling was observed in
CTLA-4–deficient T cells.25 This observation led to the proposal
that CTLA-4 functions by recruiting tyrosine phosphatases. We
have shown that normal levels of SHP-1 are not required for
CTLA-4–mediated T-cell inhibition.43 Some evidence for a role for
tyrosine phosphatase SHP-2 has been reported. Demonstration that
catalytically active SHP-2 binds to the cytoplasmic tail of CTLA-
425,44 suggests that this tyrosine phosphatase is relevant. However,
SHP-2 bound to phosphorylated polypeptides of CTLA-4 and
CD28 cytoplasmic tails,45 making the interpretation of the role of
SHP-2 in inhibitory T-cell signaling difficult. Recently serine/
threonine phosphatases PP2A and PP6 have been reported to bind
to both CTLA-4 and CD28 cytoplasmic tails,46 although the
functional significance of these interactions has not been deter-
mined. Alternative mechanisms,47-51 including competition with
CD28 for ligand47-49 or the induction of TGF- secretion,51 have
been suggested to function in some, but not all, circumstances.49,52
Further, because the activation status of the T cells, as well as the
balance of the TCR- versus CD28-mediated signals, influence the
function of CTLA-4,1 the mechanism of activation may vary under
different conditions. These complexities have impeded progress in
identifying specific intracellular signal transducers of CTLA-4, but
nevertheless, the importance of tyrosine phosphatases has been
well established and is a common theme for both Ly49- and
CTLA-4–mediated signaling pathways.
The results presented here suggest that the Ly49A-mediated
signaling pathway modifies the proximal and distal signaling
pathways in T cells activated in vivo. The molecules CD3
 and
ERK2 were found to be differentially phosphorylated in the
Ly49ATg H-2Dd CTLA-4/ compared to the CTLA-4/ T cells.
Importantly, it has been reported that CTLA-4 cross-linking on
T-cell blasts decreased the levels of phosphorylation of CD3
 and
ERK2.48,53 Although the data are suggestive of some convergence
between Ly49 and CTLA-4 negative signaling in T cells at the level
of both substrates and functional outcome, the exact biochemical
components of each pathway still remain to be elucidated. Charac-
terization of physiologically relevant protein interactions and
phosphorylation status on dominant inhibitory signaling, leading to
identification of points of convergence and divergence of the
CTLA-4– and Ly49A-mediated signals can be performed using this
model system.
CTLA-4/ T cells are arguably one of the most autoaggressive
cells found to date. The fact that other inhibitory receptors, such as
PD-1,54 which is expressed on CTLA-4/ T cells (C.A.C.,
unpublished result, February 2001), cannot compensate for the
absence of CTLA-4 clearly points to a physiologic relevance and
convergent signaling pathways used by inhibitory Ly49 molecules
and CTLA-4 in T cells. Expression of the NKR on T cells has been
observed in a number of scenarios, including recipients of alloge-
neic bone marrow transplants, aged individuals, and patients
undergoing chronic viral infections, such as in those infected with
human immunodeficiency virus, and in patients with melanoma.
The results presented in this paper demonstrate that inhibitory
NKR can regulate T-cell activation or proliferation in vivo. This
occurred in the absence of immunization or antigenic challenge,
suggesting that autoreactive peripheral T cells can be regulated by
inhibitory NKR. Hence, these results have tangible clinical implica-
tions and this model system provides a novel approach toward
understanding inhibitory NKR and CTLA-4 biology.
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